High levels of circulating VEGF and its receptors indicate a poor prognosis for breast cancer patients15, and VEGF has been identified as a critical mediator of tumor immunosuppression, by increasing the expression of immune checkpoints that mediate effector CD8+ T-cell exhaustion16–19. The gene discussed is VEGFA; the disease is breast carcinoma.